ABDI IBRAHIM ILAC SAN. VE TIC. A.S.

Non-Steroidal Antirheumatics

Platelet aggregation inhibitors (COX inhibitors)

Atypical Antipsychotics - Schizophrenia

Adrenergics (B2 agonists) in combination with corticosteroids - Asthma & COPD

Thyroid Preparations - Hypothyroidism

Antiepileptic

NSAID

PDE5 Inhibitors - Erectile dysfunction

Selective serotonin reuptake inhibitors - Antidepressants

Nucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B

Nucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B

Parkinson

Abdi İbrahim announces plans to use solar and wind energy in all of its facilities from January 1, 2020  onwards

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, were laid by the pharmacist Abdi İbrahim Bey who initiated the journey of healing by establishing a small pharmacy in 1912 in İstanbul’s Küçükmustafapaşa neighborhood. Today, collaborating with 30 licensors and developing its own products, Abdi İbrahim has the widest product portfolio in the industry with its 200+ brands and 450+ products in chemical Rx, biotechnological and OTC categories.
Thanks to its strong vision and dynamic structure, Abdi İbrahim has maintained its leadership in the Turkish pharmaceutical industry since 2002. The largest employer in the industry with 4,600 highly qualified employees, the company also stands out with the largest marketing and sales force in the industry.
At its Istanbul Esenyurt Production Complex, Abdi İbrahim manufactures its own products as well as those of a large number of global pharma companies as a CMO, including chemical Rx, biotechnologicals, hormones, ophthalmic agents and sterile products. Abdi İbrahim's R&D Center is the first accredited pharmaceutical R&D Center in Turkey.
As an EU-approved GMP facility, the Esenyurt Production Complex holds GMP certificates for Turkey, Canada, Portugal, Brazil, Russia, Ukraine, South Africa, Jordan, Peru, Saudi Arabia, Iraq, Tunisia, the Gulf countries and United Arab Emirates.
Furthermore, the company has R&D Centers and production facilities in Kazakhstan and Algeria.

Abdi İbrahim, operating in the pharmaceuticals industry for the last 108 years, and the consecutive market leader in the last 18, took part in a Swiss joint venture that acquired OM Pharma, a 83-year pharma company based in Switzerland, one of the leading countries in Pharmaceutical Industry. The acquisition made Abdi İbrahim first and only Turkish  pharma company to form a strategic partnership with a European counterpart.

Abdi İbrahim, Turkey’s leading pharmaceutical company having built the largest biotechnological manufacturing facility of the country, entered a strategic partnership with the Icelandic pharmaceutical company Alvotech to manufacture and launch biotechnology drugs in Turkey.